Cardiovascular trials are becoming harder to execute. Patient populations increasingly overlap across competing studies and sponsors who rely on the same historically top-performing sites face diminishing returns as those sites reach capacity, fatigue or age out of the pipeline.
This webinar examines how cardiovascular trial delivery is evolving from a CRO perspective. Fortrea will introduce its new Feasibility Intelligence Engine (FIE), which brings together historical experience, internal trial history and external datasets into a single, unified platform, giving teams one consolidated source of truth to identify patterns, estimate patient populations and prioritize the strongest countries and sites. For sponsors, this means faster proposal turnaround, sharper country and site prioritization, real-time scenario modeling and a meaningfully reduced risk of under-enrollment, giving them a clearer, faster path from protocol to study start.
FIE's depth of trial and real-world data provides sponsors with a sharper view of their existing site landscape and that same intelligence becomes even more powerful when paired with an actively expanding, on-the-ground site network. Dan Robitaille from Velocity, a diversified site partner working across many therapeutic areas, will share how new and non-traditional sites, particularly those with strong patient access, are identified and developed to become trial-ready, expanding the pool of sites sponsors can draw on.
Through operational and strategic lenses, the speakers will discuss how pairing trial intelligence with an actively growing site network addresses two needs at once: sharper decisions on the sites already in play today and a broader, more diverse pool for tomorrow's studies.
Designed for biotech and biopharma teams managing complex, competitive cardiovascular programs, this session brings both perspectives together to address what it actually takes to keep a cardiovascular site pool healthy, without losing time, quality or sponsor confidence.
Register for this webinar to learn how combining feasibility intelligence with site expansion can strengthen site selection, reduce enrollment risks and improve cardiovascular trials.
Who Should Attend
This webinar is designed for teams responsible for planning, starting up and delivering cardiovascular and cardiometabolic clinical trials:
Biopharma and Biotech Sponsors
Clinical Development leaders
Portfolio and Program Leads
Clinical Operations leaders
Feasibility and Site Strategy teams
Study Start-Up professionals
Patient Recruitment Leads
Site Partners and Alliance teams
Outsourcing and Vendor Strategy leaders
Data Science and Innovation teams
Investigators and Site Directors
Register free on Xtalks: https://xtalks.com/webinars/closing-the-cardiovascular-site-gap-intelligence-meets-site-expansion/
